ORAVIG Drug Patent Profile

When do Oravig patents expire, and when can generic versions of Oravig launch?

Oravig is a drug marketed by Galt Pharms and is included in one NDA.

The generic ingredient in ORAVIG is miconazole. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the miconazole profile page.

Summary for ORAVIG

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ORAVIG

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galt Pharms	ORAVIG	miconazole	TABLET;BUCCAL	022404-001	Apr 16, 2010		RX	Yes	Yes

International Patents for ORAVIG

See the table below for patents covering ORAVIG around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1408911
China	101524337
Japan	4657603
Japan	2010270142	LIVING BODY ADHESIVE TREATING SYSTEM WITH SUSTAINED RELEASE

Investment Scenario and Fundamentals Analysis for ORAVIG

Last updated: February 20, 2026

What is ORAVIG?

ORAVIG is an oral antifungal medication containing voriconazole, primarily used for the treatment of invasive fungal infections. It is marketed by Pfizer in various regions under different brand names, with a focus on serious fungal diseases such as invasive aspergillosis and candidiasis.

Market Overview and Demand Drivers

The global antifungal market was valued at approximately $11 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2028 [1]. Key drivers include:

• Rising incidence of invasive fungal infections, especially in immunocompromised patients.
• Increased awareness and earlier diagnosis.
• Expansion of antifungal indications.

ORAVIG holds a significant share within the oral antifungal segment, owing to its patent protection and inclusion in treatment guidelines. It is prescribed primarily in hospitals and specialized clinics.

Current Market Position

• Market Share: Estimated 20-25% within the oral antifungal market segment.
• Peak Sales: Pfizer reported $500 million in global sales in 2022 for voriconazole products, though sales figures vary by region and formulation.
• Key Competitive Products: Isavuconazole, posaconazole, itraconazole.

Patent Landscape and Regulatory Status

• Patent Protection: Pfizer's patent protections extend until 2025-2027 in most regions.
• Regulatory Approvals: Approved by FDA (2002), EMA (2003). Pending or approved biosimilars could impact pricing and market share post-patent expiration.

Financial Fundamentals

Metric	Data	Source
Total R&D Investment (2022)	$2.5 billion (Pfizer)	Pfizer Annual Report 2022
Estimated Cost to Develop a New Drug	$2.9 billion (including failed projects)	Tufts Center for Study of Drug Development [2]
Gross Margin	~80% for branded antifungals	Pfizer Financials
Revenue (2022)	$500 million (voriconazole segment)	Pfizer Reports

Investment Risks

• Patent expiration potentially erodes market share.
• Competition from biosimilars and emerging antifungal agents.
• Pricing pressures due to healthcare policy reforms.
• Regulatory delays for new indications or formulations.

Growth and Development Opportunities

• New formulations, such as IV-to-oral switches, improve adherence.
• Expansion into emerging markets.
• Development of generics post-patent expiration, potentially leading to increased volume sales.
• Investigations into new indications for resistant fungal strains.

Competitive Landscape

Company	Product Name	Patent Status	Market Share	Price Competitiveness
Pfizer	ORAVIG (voriconazole)	Patent until 2025-2027	20-25%	Premium pricing
Basilea Pharma	Isavuconazole	Patent until 2028	~15%	Slightly lower
Merck	Posaconazole	Patent until 2026	~10%	Comparable
Generic manufacturers	Voriconazole (generics)	Patent expired/expiring	N/A	Lower cost

Financial Outlook and Scenarios

Base Scenario (Patent protection maintained through 2025):

• Steady revenue growth of 3-4% annually.
• Gross margins maintained at 80%.
• Stable market share.

Downside Scenario (Post-patent expiry in 2025):

• Revenue declines by 50-60% over 3 years due to generics.
• Margins decrease to 50-60%.
• Market share shifts rapidly to generics or biosimilars.

Upside Scenario (New indications or formulations approved):

• Potential revenue uplift of 10-15% annually.
• Increased dosing flexibility and improved margins.

Key Takeaways

• ORAVIG remains a high-value asset for Pfizer due to its market position and patent protections.
• The approaching patent expiry poses significant revenue risks, emphasizing the importance of pipeline development and market expansion.
• Competitive pressures and biosimilar entry will impact future profitability.
• Opportunities exist in pipeline expansion and market penetration in emerging economies.
• Financial stability depends on maintaining market share, controlling costs, and timely approval of new formulations.

Frequently Asked Questions

1. What is the primary market for ORAVIG?
Hospitals and specialized care clinics serve as the primary markets, particularly in regions with high incidences of invasive fungal infections.

2. How does patent expiration influence ORAVIG’s valuation?
Patent expiry around 2025-2027 risks significant revenue declines due to generic competition, which can erode profit margins and market share.

3. Are biosimilars a threat to ORAVIG?
Biosimilars target biologic drugs, not small molecule antifungals like voriconazole. However, generic formulations of voriconazole will challenge branded sales.

4. What growth strategies could Pfizer pursue?
Developing new formulations, expanding into emerging markets, and investigating new indications for resistant fungal strains.

5. How do current patent protections impact investment decisions?
Patent protections provide a temporal window of market exclusivity, supporting premium pricing and revenue stability until 2025-2027.

---

References

1. MarketWatch. (2023). Antifungal Market Size & Trends.
2. Tufts Center for Study of Drug Development. (2022). Cost and timelines for new drug development.
3. Pfizer Inc. Annual Report. (2022). Financial Statements and Business Overview.